Probable trimethoprim/sulfamethoxazole-induced higher-level gait disorder and nocturnal delirium in an elderly man

Annals of Pharmacotherapy

Volumn 43, Issue 1, 2009, Pages 129-133

  Dakin, Lucy E ^a,b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Gait apraxia; Higher level gait disorder; Trimethoprim sulfamethoxazole

Indexed keywords

AMPICILLIN; CEFEPIME; COTRIMOXAZOLE; ESCITALOPRAM; ESOMEPRAZOLE; HEPARIN; MULTIVITAMIN; OMEPRAZOLE; OXAZEPAM; PIPERACILLIN PLUS TAZOBACTAM; SUPRADYN; THIAMINE; VENLAFAXINE;

AGED; ARTICLE; ARTIFICIAL VENTILATION; ASPIRATION PNEUMONIA; BACTERIUM ISOLATION; BALANCE DISORDER; CASE REPORT; DELIRIUM; DRUG DOSE INCREASE; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FALLING; GAIT DISORDER; HUMAN; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG ABSCESS; MALE; MALNUTRITION; NARANJO PROBABILITY SCALE; NONHUMAN; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; SPUTUM ANALYSIS; STENOTROPHOMONAS MALTOPHILIA; SYMPTOMATOLOGY; CHEMICALLY INDUCED; COMPLICATION; DYSSOMNIAS; GAIT DISORDERS, NEUROLOGIC; VERY ELDERLY;

AGED, 80 AND OVER; DELIRIUM; DYSSOMNIAS; GAIT DISORDERS, NEUROLOGIC; HUMANS; MALE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 58549098725     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L295     Document Type: Article

References (26)

1. Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim- sulfamethoxazole revisited. Arch Intern Med 2003;163:402-10. DOI 10.1001/archinte.163.4.402
2. Nutt JG, Marsden CD, Thompson PD. Human walking and higher-level gait disorders, particularly in the elderly. Neurology 1993;43:267-79.
3. Liston R, Mickelborough J, Bene J, Tallis R. A new classification of higher level gait disorders in patients with cerebral multi-infarct states. Age Ageing 2003;32:252-8. DOI 10.1093/ageing/32.3.252
4. Wilson RK, Williams MA. Normal pressure hydrocephalus. Clin Geriatr Med 2006;22:935-51. DOI 10.1016/j.cer.2006.06.010
5. Tyrell PJ. Apraxia of gait or higher-level gait disorders: review and description of two cases of progressive gait disturbance due to frontal lobe degeneration. J R Soc Med 1994;87:454-6.
6. Martin MP, O'Neill D. Vascular higher-level gait disorders - a step in the right direction? Lancet 2004;363:8. DOI 10.1016/S0140-6736(03)15246-4
7. Capra C, Mario G, Monza Meazza G, Ramella G. Trimethoprim- sulfamethoxazole-induced aseptic meningitis: case report and literature review. Intensive Care Med 2000;26:212-4. DOI 10.1007/s001340050048
8. Dib EG, Bemstein S, Benesch C. Multifocal myoclonus induced by trimethoprim-sulfamethoxazole therapy in a patient with Nocardia infection. N Engl J Med 2004;350:88-9. DOI 10.1056/NEJM200401013500121
9. Jundt F, Lempert T, Dorken B, Pezzutto A. Trimethoprim-sulphamethoxazole exacerbates posthypoxic action myoclonus in a patient with suspicion of Pneumocystis jiroveci infection. Infection 2004;32:176-8. DOI 10.1007/s15010-004-3011-6
10. Van Gerpen JA. Tremor caused by trimethoprim-sulfamethoxazole in a patient with AIDS. Neurology 1997;48:537-8.
11. Bua J, Marchetti F, Barbi E, Sarti A, Ventura A. Tremors and chorea induced by trimethoprim-sulfamethoxazole in a child with Pneumocystis pneumonia. Pediatr Infect Dis J 2005;24:934-5. DOI 10.1097/01.inf. 000018047223898.7e
12. Patterson RG, Couchenour RL. Trimethoprim-sulfamethoxazole-induced tremor in an immunocompetent patient. Pharmacotherapy 1999;19:1456-8. DOI 10.1592/phco.19.18.1456.30903
13. Saidinejad M, Burns Ewald M, Shannon MW. Transient psychosis in an immune-competent patient after oral trimethoprim-sulphamethoxazole administration. Paediatrics 2005;115:739-41. Epub 2 May 2005. DOI 10.1542/peds.2004-1352
14. Weis S, Karagulle D, Kornhuber J, Bayerlein K. Co-trimoxazole-induced psychosis: a case report and review of literature. Pharmacopsychiatry 2006;39:236-7. DOI 10.1055/s-2006-950393
15. Septra (trimethoprim-sulphamethoxazole). Mississauga, Ontario: GlaxoSmithKline Inc., revised January 7, 2008. www.gsk.ca/english/docs-pdf/ Septra-PM-20080807-EN.pdf (accessed 2008 May 7).
16. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
17. Pirmohamed M, Alfervic A, Vilar J, et al. Association analysis of drug metabolising enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000;10:705-13. DOI 10.1097/00008571-200011000-00005
18. Stevens RC, Laizure SC, Williams CL, Stein DS. Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. Antimicrob Agents Chemother 1991;35:1884-90.
19. Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother 2003;57:145-55. DOI 1016/S0753-3322(03)00043-X
20. Wu G, Fang Y, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr 2004;134:489-92.
21. Norman K, Pichard C, Lochs H, Pirlich M. Prognostic impact of disease-related malnutrition. Clin Nutr 2008;27:5-15. Epub 3 Dec 2007. DOI 10.1016/j.clnu.2007.10.007
22. Gariballa SE. Malnutrition in hospitalized elderly patients: when does it matter? Clin Nutr 2001;20:487-91. DOI 10.1054/clnu.2001.0477
23. Verona L, Ruiz J, Zarranz JJ. Gait ataxia during omeprazole therapy. Ann Pharmacother 1996;30:192.
24. Bruce T, Vanderhoff MD, Rundsarah M, Tahboub MD. Proton pump inhibitors: an update. Am Fam Physician 2002;66:273-80.
25. Li X, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome activities. Drug Metab Dispos 2004;32:821-7. DOI 10.1124/dmd.32.8.821
26. Package insert. Effexor XR capsules (venlafaxine hydrochloride), 2007. Saint Laurent, Quebec: Wyeth Canada, revised Jan 10. www.wyeth.ca/en/products/ Product%20Monographs%20PDFs/Effexor%20Product%20MONOGRAPH%2010Jan07.pdf (accessed 2008 May 7)